Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

As of 2019, 62 insulin products had been removed from the market. Luckily, there are many alternative insulins, both rapid-acting and long-acting. Zilbermint highlights Lantus (insulin glargine ...

Americans with a prescription for Lantus-branded insulin, regardless of insurance status, can now get the life-saving drug for only $35. Healthcare company GoodRx announced Thursday a partnership ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of ... per month price cap on Lantus for those with private insurance. Sanofi's changes follow in the footsteps ...

1,2 The findings of these studies suggest that administration of the long-acting analog insulin glargine increases the risk of cancer in patients with diabetes mellitus, whereas the biguanide ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...